Asclepii

Cell therapy is the future of human health, with the potential to address underlying causes of disease, reduce the severity of illness, and reduce healthcare utilization. However, current cell therapies have high upfront costs and operating expenses, requiring complex and hard-to-scale infrastructure to execute, severely limiting their accessibility and potential and costing from $30–45K USD per treatment on average. The centerpiece of regenerative therapies (including but not limited to hematopoietic, myocardial, neural, and skeletal repair therapies) is the scaffold, which acts as the growth-inducing environment for cells. However, current scaffolds such as decellularized fish skin (Kerecis, acq. US$1.3 B Jul 2023) or bovine intestines (Healthpoint, acq. US$780MM 2012) are highly complex, application-specific, and costly. There is a pressing need for novel, more cost-effective, and versatile scaffolds capable of creating more accessible and effective cell therapies.

Over US$1 MM raised in non-dilutive funding R&D Partnerships in 7 countries 22.000 sq ft manufacturing plant commitment 2024 SXSW Pitch Finalist 2024 Hult Prize Summit Finalist 2024 Morgenthaler-Pavey Startup Competition Science Track Winner

• 
  Asclepii Secures $500K Grant to Transform Regenerative Wound Healing Innovation

  Signalbase · Apr 10, 2025

  Asclepii, a trailblazer in regenerative medicine and a renowned US-based medical device company, proudly announced a recent funding milestone by raising $500,000. This investment marks a pivotal moment as the company continues its powerful pursuit of revolutionizing wound healing through groundbreaking technology and innovative medical devices. Asclepii’s mission is to tackle some of the most challenging health problems facing humanity today, leveraging clinical expertise and advanced research to design and manufacture international healthcare solutions that transform lives. The funds raised will be strategically allocated towards accelerated research and development initiatives, aimed at enhancing the performance and accessibility of their regenerative therapies. In addition, the investment will support the expansion of manufacturing capabilities, enabling the company to advance clinical trials and expedite the broader commercial adoption of its cutting-edge wound healing products. With a commitment to delivering impactful healthcare solutions globally, Asclepii envisions a future where patients benefit from rapid healing and improved outcomes, regardless of geographical or economic barriers. The newly acquired capital will also bolster partnerships with academic institutions and healthcare providers, further solidifying Asclepii’s reputation as an international healthcare technology designer and manufacturer. By addressing a critical unmet need in regenerative medicine, the company is not only transforming the way wounds are treated but also setting the stage for innovation that could redefine patient care across the globe. This funding announcement is a testament to investor confidence in Asclepii’s vision and underscores a shared resolve to foster accessible, life-changing technologies that turn promising research into real-world medical breakthroughs.

• 
  A CWRU senior's startup is heading to SXSW Pitch competition

  www.crainscleveland.com

  Asclepii, launched by Case Western Reserve University biomedical engineering student Franco Kraiselburd to use stem cells to improve wound care, is a finalist in the student category for the 15th annual SXSW Pitch, formerly known as SXSW Accelerator.

• 
  Cleveland Startup Asclepii Launches FDA-Cleared Wound Care Product, Poseidon™ - PR.com

  PR.com

  Cleveland-based healthcare startup Asclepii is announcing the official launch of Poseidon™, an FDA-cleared nanosilver hydrogel engineered to accelerate...